Molecular Subtype
Hormone Receptor-Positive Breast Carcinoma
CI-CAN-00005524Explore in graph →
36 active trials1 approved drugs
- NCIt
- C157056
Loading cancer entity…
Loading cancer entity…
Molecular Subtype
CI-CAN-00005524Explore in graph →
Clinical trials
67 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (14)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06745804 | Study of 68Ga-R10602 | completed | Phase 1 | 27 | Radionetics OncologyINDUSTRY | 1 | Jul 6, 2026 | clinicaltrials |
| NCT04505826 | A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer | completed | Phase 1 / Phase 2 | 153 | Olema Pharmaceuticals, Inc.INDUSTRY | 2 | May 11, 2026 | clinicaltrials |
| NCT04481113 |
| Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer |
| completed |
| Phase 1 |
| 8 |
| OHSU Knight Cancer InstituteOTHER |
| 1 |
| Jan 29, 2026 |
| clinicaltrials |
| NCT06106282 | Breast Cancer Survivors Who Experience Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS) | completed | — | 105 | Mayo ClinicOTHER | 1 | Oct 31, 2025 | clinicaltrials |
| NCT02003209 | Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer | completed | Phase 3 | 315 | National Cancer Institute (NCI)NIH | 2 | Aug 8, 2025 | clinicaltrials |
| NCT05173103 | Retrospective Study of 2nd-line Therapies After CDK4/6i + Hormonal Therapy in HR+/HER2- Advanced Breast Cancer(HERMIONE-13) | completed | — | 254 | University of Milano BicoccaOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT03251378 | A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast Cancers | completed | Phase 1 | 129 | Hutchison Medipharma LimitedINDUSTRY | 1 | Sep 25, 2024 | clinicaltrials |
| NCT04797728 | Elacestrant in Preoperative Setting, a Window of Opportunity Study(ELIPSE) | completed | Early Phase 1 | 23 | SOLTI Breast Cancer Research GroupOTHER | 1 | Oct 26, 2022 | clinicaltrials |
| NCT02152943 | Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients | completed | Phase 1 | 37 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 19, 2020 | clinicaltrials |
Data updated 22 days agoSource updated Jul 6, 2026source: clinicaltrials